海洋医薬品の世界市場2021年-2025年

◆英語タイトル:Global Marine Pharmaceuticals Market 2021-2025
◆商品コード:IRTNTR70227
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年2月27日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他の地域
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社の本調査レポートでは、世界の海洋医薬品市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、製品別(腫瘍、心血管、抗感染薬、その他)分析、発生源別(無脊椎動物、脊椎動物、その他)分析、顧客状況、地域別状況、企業状況、企業分析などの項目を掲載しています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の海洋医薬品市場規模:製品別(腫瘍、心血管、抗感染薬、その他)
・世界の海洋医薬品市場規模:発生源別(無脊椎動物、脊椎動物、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Marine Pharmaceuticals Market 2021-2025
Technavio has been monitoring the marine pharmaceuticals market and it is poised to grow by $ 1.43 bn during 2021-2025 progressing at a CAGR of 8% during the forecast period. Our report on marine pharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the licensing agreements, special drug designations, and vast availability of raw materials. In addition, licensing agreements is anticipated to boost the growth of the market as well.
The marine pharmaceuticals market analysis includes product segment and geographical landscapes.
Technavio’s marine pharmaceuticals market is segmented as below:

By Product
• Oncology
• Cardiovascular
• Anti-infectives
• Others

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies the marine peptides as anti-infectives as one of the prime reasons driving the marine pharmaceuticals market growth during the next few years. Also, research for anti-inflammatory compounds from marine sources and increasing clinical trials will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on marine pharmaceuticals market covers the following areas:
• Marine pharmaceuticals market sizing
• Marine pharmaceuticals market forecast
• Marine pharmaceuticals market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading marine pharmaceuticals market vendors that include BeyondSpring Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Pfizer Inc., PharmaMar SA, F. Hoffmann-La Roche Ltd., Seagen Inc., and TerSera Therapeutics LLC. Also, the marine pharmaceuticals market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/marine-pharmaceuticals-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Oncology – Market size and forecast 2020-2025
o Cardiovascular – Market size and forecast 2020-2025
o Anti-infectives – Market size and forecast 2020-2025
o Others – Market size and forecast 2020-2025
o Market opportunity by Product
• Market Segmentation by Source
o Invertebrate
o Vertebrate
o Others
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o BeyondSpring Inc.
o Bristol-Myers Squibb Co.
o Eisai Co. Ltd.
o GlaxoSmithKline Plc
o Jazz Pharmaceuticals Plc
o Pfizer Inc.
o PharmaMar SA
o F. Hoffmann-La Roche Ltd.
o Seagen Inc.
o TerSera Therapeutics LLC
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Product – Market share 2020-2025 (%)
• 22: Comparison by Product
• 23: Oncology – Market size and forecast 2020-2025 ($ million)
• 24: Oncology – Year-over-year growth 2020-2025 (%)
• 25: Cardiovascular – Market size and forecast 2020-2025 ($ million)
• 26: Cardiovascular – Year-over-year growth 2020-2025 (%)
• 27: Anti-infectives – Market size and forecast 2020-2025 ($ million)
• 28: Anti-infectives – Year-over-year growth 2020-2025 (%)
• 29: Others – Market size and forecast 2020-2025 ($ million)
• 30: Others – Year-over-year growth 2020-2025 (%)
• 31: Market opportunity by Product
• 32: Customer landscape
• 33: Market share by geography 2020-2025 (%)
• 34: Geographic comparison
• 35: North America – Market size and forecast 2020-2025 ($ million)
• 36: North America – Year-over-year growth 2020-2025 (%)
• 37: Europe – Market size and forecast 2020-2025 ($ million)
• 38: Europe – Year-over-year growth 2020-2025 (%)
• 39: Asia – Market size and forecast 2020-2025 ($ million)
• 40: Asia – Year-over-year growth 2020-2025 (%)
• 41: ROW – Market size and forecast 2020-2025 ($ million)
• 42: ROW – Year-over-year growth 2020-2025 (%)
• 43: Key leading countries
• 44: Market opportunity by geography ($ million)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: BeyondSpring Inc. – Overview
• 52: BeyondSpring Inc. – Product and service
• 53: BeyondSpring Inc. – Key offerings
• 54: BeyondSpring Inc. – Key customers
• 55: BeyondSpring Inc. – Segment focus
• 56: Bristol-Myers Squibb Co. – Overview
• 57: Bristol-Myers Squibb Co. – Product and service
• 58: Bristol-Myers Squibb Co. – Key offerings
• 59: Bristol-Myers Squibb Co. – Key customers
• 60: Bristol-Myers Squibb Co. – Segment focus
• 61: Eisai Co. Ltd. – Overview
• 62: Eisai Co. Ltd. – Business segments
• 63: Eisai Co. Ltd. – Key offerings
• 64: Eisai Co. Ltd. – Key customers
• 65: Eisai Co. Ltd. – Segment focus
• 66: GlaxoSmithKline Plc – Overview
• 67: GlaxoSmithKline Plc – Business segments
• 68: GlaxoSmithKline Plc – Key offerings
• 69: GlaxoSmithKline Plc – Key customers
• 70: GlaxoSmithKline Plc – Segment focus
• 71: Jazz Pharmaceuticals Plc – Overview
• 72: Jazz Pharmaceuticals Plc – Business segments
• 73: Jazz Pharmaceuticals Plc – Key offerings
• 74: Jazz Pharmaceuticals Plc – Key customers
• 75: Jazz Pharmaceuticals Plc – Segment focus
• 76: Pfizer Inc. – Overview
• 77: Pfizer Inc. – Business segments
• 78: Pfizer Inc. – Key offerings
• 79: Pfizer Inc. – Key customers
• 80: Pfizer Inc. – Segment focus
• 81: PharmaMar SA – Overview
• 82: PharmaMar SA – Business segments
• 83: PharmaMar SA – Key offerings
• 84: PharmaMar SA – Key customers
• 85: PharmaMar SA – Segment focus
• 86: F. Hoffmann-La Roche Ltd. – Overview
• 87: F. Hoffmann-La Roche Ltd. – Business segments
• 88: F. Hoffmann-La Roche Ltd. – Key offerings
• 89: F. Hoffmann-La Roche Ltd. – Key customers
• 90: F. Hoffmann-La Roche Ltd. – Segment focus
• 91: Seagen Inc. – Overview
• 92: Seagen Inc. – Business segments
• 93: Seagen Inc. – Key offerings
• 94: Seagen Inc. – Key customers
• 95: Seagen Inc. – Segment focus
• 96: TerSera Therapeutics LLC – Overview
• 97: TerSera Therapeutics LLC – Product and service
• 98: TerSera Therapeutics LLC – Key offerings
• 99: TerSera Therapeutics LLC – Key customers
• 100: TerSera Therapeutics LLC – Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations



【掲載企業】

BeyondSpring Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Pfizer Inc., PharmaMar SA, F. Hoffmann-La Roche Ltd., Seagen Inc., TerSera Therapeutics LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[海洋医薬品の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆